Flexion’s Zilretta Shows Positive Results in Phase 3 Trial

Flexion Therapeutics’ osteoarthritis candidate Zilretta shined in a Phase 3 study, meeting its primary endpoint of statistically significant pain relief at week 12 compared with placebo.

Patients treated with Zilretta experienced on average a 50 percent reduction in pain from baseline against placebo. No serious drug-related adverse events were observed during the trial.